Drug Interaction Report

Mavorixafor may increase the blood levels of leniolisib. You may need a dose adjustment or more frequent monitoring to safely use both medications. Contact your healthcare provider if you have any questions, your condition changes, or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Mavorixafor should be taken on an empty stomach after an overnight fast, 30 minutes before food. Do not consume grapefruit products during treatment with mavorixafor unless otherwise directed by your doctor. Grapefruit juice can increase the blood levels and adverse effects of mavorixafor, increasing the risk of experiencing a change in the electrical activity of your heart called QT prolongation, which can result in irregular heartbeats that can be life-threatening. You should seek immediate medical attention if you experience an irregular heartbeat or feel dizzy, lightheaded, or faint during treatment. Speak with your doctor or healthcare provider if you have any questions. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inhibitors of CYP450 3A4 including grapefruit or grapefruit juice may increase the plasma concentrations of leniolisib, which undergoes extensive CYP450 3A4-mediated first-pass metabolism in the gut wall and liver. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.

MANAGEMENT: Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of leniolisib. Some authorities recommend to avoid grapefruit products during leniolisib treatment (UK).